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A previously undescribed coronavirus (CoV) is the etiologic agent
responsible for severe acute respiratory syndrome (SARS). Using a
panel of contiguous cDNAs that span the entire genome, we have
assembled a full-length cDNA of the SARS-CoV Urbani strain, and
have rescued molecularly cloned SARS viruses (infectious clone
SARS-CoV) that contained the expected marker mutations inserted
into the component clones. Recombinant viruses replicated
as efficiently as WT virus and both were inhibited by treatment
with the cysteine proteinase inhibitor (2S,3S)-transepoxysuccinyl-
L-leucylamido-3-methylbutane ethyl ester. In addition, subgenomic
transcripts were initiated from the consensus sequence ACGAAC in
both the WT and infectious clone SARS-CoV. Availability of a
SARS-CoV full-length cDNA provides a template for manipulation
of the viral genome, allowing for the rapid and rational develop-
ment and testing of candidate vaccines and therapeutics against
this important human pathogen.
Severe acute respiratory syndrome (SARS) is a life-threatening respiratory disease that probably originated in
Guangdong Province, China, in the fall of 2002 (1, 2). A
previously undescribed coronavirus (CoV), isolated from febrile
and dying patients, is the etiologic agent responsible for the
disease (3–8). SARS-CoV infection is associated with overall
case fatality rates thought to approach 14–15%, with selected
populations being at increased risk (www.who.intcsrsars
archive20030507aen). SARS-CoV infected 8,000 individ-
uals and caused 800 deaths (www.who.intcsrsarsen) before
aggressive infection control measures successfully contained the
scope of the outbreak. Despite intensive efforts, no effective
antiviral treatments against SARS have been described.
CoVs, members of the order Nidovirus, contain the largest
single-stranded, positive-polarity RNA genome in nature and
are divided into three main serogroups, group I CoVs: trans-
missible gastroenteritis virus (TGEV) and human CoV 229E
(HCV-229E), group II: mouse hepatitis virus (MHV) and bovine
CoV, and group III: infectious bronchitis virus (IBV). Although
initial phylogenetic comparisons suggested that SARS-CoV may
represent the prototype strain of group IV (6, 8–10), more recent
analyses characterized SARS-CoV as an early split-off among
group II (11). The SARS-CoV genomic RNA is 29,700 bp in
length and has several large ORFs encoded in subgenomic and
full-length mRNAs (8–10). The subgenomic mRNAs comprise
a nested set of 3-coterminal molecules in which the leader RNA
sequences, encoded at the 5 end of the genome, are joined to
body sequences at distinct transcription regulatory sequences
containing a highly conserved consensus sequence (CS). The
exact SARS CS has been predicted as either CUAAAC or
AAACGAAC (8, 9). The SARS-CoV genome-length RNA is
likely encapsidated by multiple 50-kDa nucleocapsid proteins
(N) (8). As with other CoVs, the virion contains several viral
structural proteins including the spike glycoprotein of140 kDa
(S), a 23-kDa membrane glycoprotein (M), and an 10-kDa E
protein.
The CoV gene 1, or replicase gene, comprises two-thirds of the
genome. MHV and SARS-CoV contain two overlapping ORFs,
ORF1a and ORF1b, which are connected by a ribosomal frame
shift (Fig. 1A). In MHV, three proteinases, papain-like protein-
ases 1 and 2 (11–14) and 3C-like proteinase, mediate cleavage of
the polyproteins into at least 15 mature proteins (11, 15). The
SARS virus replicase gene is predicted to encode only the
papain-like proteinase 2 and 3C-like proteinases (6, 7).
Continuous polyprotein processing is crucial for ongoing virus
transcription; therefore, MHV replication is sensitive to protease
inhibitors that prevent replicase processing (12). Additional
functions have been predicted for proteins processed from the
replicase polyprotein, including an RNA-dependent RNA poly-
merase (pol), an RNA helicase (hel), a capping enzymatic
activity, and several putative RNA-processing enzymatic activ-
ities (6, 11, 16). In this article, we recover recombinant SARS-
CoV from a full-length cDNA of the genome by using an
approach that will allow for rapid genetic analysis of SARS-CoV
protein functions and replication.
Experimental Procedures
Virus and Cells. The Urbani and Canadian strains (Tor-2 and
Tor-7) of SARS-CoV were propagated in VeroE6 cells in MEM
supplemented with 10% FCS, kanamycin (0.25 gml), and
gentamyacin (0.05 gml) at 37°C in a CO2 incubator. Cultures
of VeroE6 cells were infected at a multiplicity of infection of
0.1 for 30 min, washed, and titered by plaque assay. At 1 h
after infection, some cultures were treated with the cysteine
protease inhibitor (2S,3S)-transepoxysuccinyl-L-leucylamido-3-
methylbutane ethyl ester (E64-d) at a concentration of 500
gml. Virus plaques were visualized by neutral red staining at
2 d after infection. MHV-A59 was grown as described in the
presence or absence of E64-d (12, 17).
Strategy for Cloning the SARS-CoV cDNAs. Reverse transcription
was performed by using SuperScript II, oligodeoxynucleotide
primers, and intracellular RNA from SARS-infected cultures
(17, 18). The cDNA was denatured for 2 min at 94°C and
amplified by PCR with Expand Long TAQ polymerase (Roche
Molecular Biochemicals) for 25 cycles at 94°C for 30 sec, 58°C
for 25–30 sec, and 68°C for 1–7 min. The amplicons were cloned
into Topo II TA (Invitrogen) (SARS subclones D–F) or in
pSMART vectors (Lucigen, Middleton, WI) (SARS subclones
A–C). All cDNAs were assembled as CSs based on independent
sequence analysis of four to seven sibling clones and the reported
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Urbani sequence (8). The following primers were used in the
isolation of the SARS A subclone (forward, tactaatacgactcac-
tatagatattaggtttttacctacccagg-1, reverse, acaccatagtcaacgatgcc-
4452); SARS B subclone (forward, gcctatatgcatggatgttagat-4359,
reverse, tgaaccgccacgctggctaaacc-8727); SARS C, subclone (for-
ward, agccagcgtggcggttcatac-8710, reverse, aggcctcttgggcagtg-
gcataag-12085); SARS D subclone (forward, actgcccaagatgcctat-
gagc-12070, reverse, cagccaggagggcagacttcacaacc-18939); SARS
E subclone (forward, gtctgccctcctggctgataagtttccag-18923,
reverse, gagcagccgtgtaggcagcaat-24066); and SARS F subclone
(forward, attgctgcctacacggctgctc-24045 reverse, (ttt)7gtcattctcc-
taagaagc-29710).
To repair sibling clones, primer pairs were designed that con-
tained a class IIS restriction enzyme, like AarI. By using high fidelity
PCR, the consensus portions of different sibling clones were
amplified, digested with AarI, and ligated into plasmid. The AarI
junctions were designed to seamlessly link consensus fragments,
resulting in the production of a full-length cDNA fragment for each
of the various SARS cDNA subclones (17). By using an automated
Applied Biosystems DNA sequencer, two to three candidate DNAs
were sequenced to identify the consensus clone.
Systematic Assembly of a Full-Length SARS-CoV cDNA. The SARS
A–F inserts were restricted, separated through 0.8% agarose
gels, visualized with a darkreader lightbox (Clare Chemical
Research, Dolores, CO), excised, and purified by using the Qiaex
II DNA purification kit. The SARS A  B, C  D, and E  F
subclones were ligated overnight and isolated (17, 18). The
SARS AB  CD  EF cDNAs were ligated overnight at 4°C,
phenolchloroform extracted and precipitated. Transcripts were
generated in vitro (TmMessage mMachine, Ambion) as de-
scribed by the manufacturer with certain modifications (17). For
SARS N transcripts, 1 g of plasmid DNA encoding the N gene
(primer: 5-nnggcctcgatggccatttaggtgacactatagatgtctgataatgg-
accccaatc-3 and reverse primer (5-nnnttttttttttttttttttttttttt-
tatgcctgagttgaatcagcag-3) were transcribed by SP6 RNA poly-
merase with a 2:1 ratio of cap analog to GTP.
Transfection of Full-Length Transcripts. RNA transcripts were
added to 800l of the BHK cell suspension (8.0 106), and three
electrical pulses of 850 V at 25 F were given with a Gene Pulser
II electroporator (Bio-Rad) (17, 18). The BHK cells were seeded
with 1.0–2.0  106 VeroE6 cells in a 75-cm2 flask and incubated
at 37°C for 2 d. Virus progeny were then purified by plaque assay.
For fluorescent Ab staining, cells were washed in PBS and
incubated with goat serum for 20 min at room temperature. The
cells were washed, incubated with a 1:200 dilution of MHV
polyclonal antiserum that cross reacts with the SARS N protein,
and then incubated in Alexa 488 diluted 1:400 for 30 min. The
cells were fixed in 10% neutral, phosphate-buffered formalin for
24 h, rinsed for 30 min, and visualized under a fluorescent
microscope.
Detection of Marker Mutations Inserted in Infectious Clone (ic)SARS-
CoV. Intracellular RNA was isolated from either WT or icSARS-
CoV-infected cells at 24 h after infection. After RT-PCR, we
obtained a 1668-nt amplicon (nucleotide positions 1007–2675)
spanning the BglI site at position 1557 that had been ablated in
the icSARS-CoV component clones, but not WT SARS-CoV.
Other PCR products included a 799-nt amplicon spanning the
mRNAs (8). (B) Several BglI-interconnecting junctions were inserted between
the component clones to allow assembly of a full-length cDNA. Lowercase
letters represent WT sequence and numbers represent nucleotide positions in
genome. (C) ‘‘No see’m’’ Aar I repair of SARS sibling clones. Asterisks represent
sites of mutation. Numbers in bold represent portions of sibling clones that
were assembled into a consensus SARS F subclone.
Fig. 1. Assembly of a full-length SARS-CoV cDNA. (A) Structure of the
SARS-CoV genome (8, 9). The SARS Urbani29,727-bp genome contains 10 or
more ORFs, which are expressed from full-length and subgenomic-length
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SARS-CoV BC junction (nucleotide positions 8381–9180), a
544-nt amplicon (nucleotide positions 11721–12265) spanning
the SARS-CoV CD junction, a 652-nt amplicon spanning the
SARS-CoV DE junction, and a 1594-nt amplicon (nucleotide
positions 23665–25259) spanning the SARS-CoV EF junction.
The 1594-nt SARS EF junction-containing amplicon was sub-
cloned and sequenced.
RT-PCR of Leader-Containing Transcripts. Leader-containing ampli-
cons were obtained from WT and icSARS-CoV-infected cells by
using primers at the 3 end of the genome (5-tttttttttttttttttttt-
tgtcattctcctaagaagc29710-3) or in the X5 or X3 ORFs (5-
ttaattaattaatttgttcgtttatttaaaacaaca28091-3, 5-ttaattaattatggata-
atctaactccataggttct27238-3) and in the SARS leader RNA
sequence at the 5 end of the genome (5-aaagccaaccaacctcgatc-
3; nucleotides 26–35). Leader-containing amplicons were sub-
cloned into TopoII vectors and sequenced.
Results
Assembly of SARS Full-Length cDNAs. Rapid response and control
of exigent emerging pathogens requires an approach to quickly
generate full-length cDNAs from which molecularly cloned
viruses are rescued, allowing for genetic manipulation of the
genome. Full-length cDNAs were isolated for TGEV, HCoV-
229E, IBV, and MHV-A59 by using a variety of approaches
(17–21). Our strategy includes a panel of cDNAs spanning the
entire CoV genome, which can be systematically and direction-
ally assembled into a genome-length cDNA by in vitro ligation
(17, 18). The SARS genome was cloned as six contiguous
subclones that could be systematically linked by unique BglI
restriction endonuclease sites (Fig. 1). BglI is a class IIS restric-
tion endonuclease that cleaves the symmetrical sequence
GCCNNNN2NGGC but leaves 64 different asymmetrical ends.
Consequently, pairs of contiguous subclones encoded junctions
that allow unidirectional assembly of intermediates into a full-
length cDNA. As shown in Fig. 1 A, two BglI junctions were
derived from sites encoded within the SARS-CoV genome at
nucleotide positions 4373 (AB junction) and 12065 (CD
junction) (8–10). A third BglI site at nucleotide position 1577 was
removed and new BglI sites were inserted by the introduction of
silent mutations into the SARS-CoV sequence at nucleotide
8700 (BC junction), nucleotide 18916 (DE junction), and at
nucleotide 24040 (EF junction) (Fig. 1B). As described with
MHV and TGEV, SARS-CoV sequence toxicity was circum-
vented by disruption of toxic domains and the use of stable
cloning vectors (17). The resulting cDNAs include SARS A
(nucleotides 1–4436), SARS B (nucleotides 4344–8712), SARS
C (nucleotides 8695–12070), SARS D (nucleotides 12055–
18924), SARS E (nucleotides 18907–24051), and SARS F (nu-
cleotides 24030–29736) subclones. The SARS A subclone con-
tains a T7 promoter and the SARS F subclone terminates in
21Ts, allowing for in vitro transcription of capped, polyadenyl-
ated transcripts.
Numerous mutations were noted in each of the four to seven
sibling subclones encoding a given SARS cDNA fragment (Fig.
1C). To rapidly assemble consensus clones, we used class IIS
restriction endonucleases that cut at asymmetric sites and leave
asymmetric ends. These enzymes generate strand-specific
unique overhangs that allow the seamless ligation of two cDNAs
with the concomitant loss of the restriction site (17). As illus-
trated with the SARS F sibling subclones, primers were designed
that contained terminal Aar I (CACCTGCNNNN2NNNN) sites
that flanked each of the various consensus portions of different
sibling clones. In some instances (amplicons 3 and 2 in sibling
clones 1 and 4, respectively), the primers repaired specific
mutations located near the ends of a given amplicon (Fig. 1C).
The combination of high-fidelity PCR, oligonucleotide primer
repair, and the seamless ligation of sequence fragments(17),
rapidly generated Urbani consensus cDNAs for each of the
SARS A, B, C, D, E, and F subclones (Fig. 1C). Silent changes
retained in the full-length construct included an A to G change
at nucleotide position 6460, a T to C at nucleotide position 14178,
a T to C at nucleotide position 15740, a C to T at nucleotide
position 19814, an A to G at nucleotide position 20528, and a T
to C at nucleotide position 20555.
Rescue of Molecularly Cloned SARS-CoV. To build a full-length
SARS-CoV cDNA, subclones were digested with the appropri-
ate restriction enzymes, ligated together, and used as template
for in vitro transcription with the T7 RNA polymerase. Because
N transcripts enhance infectivity of TGEV and MHV transcripts
(17, 22), and are essential for IBV transcript infectivity (20),
SARS-CoV full-length transcripts were tested alone or mixed
with SARS-CoV N transcripts and electroporated into cells.
Within 48 h, SARS-CoV-infected cells were detected by fluo-
rescent Ab staining (Fig. 2 A–C). Rescued recombinant virus
(icSARS-CoV) titers approached 1.0  106 plaque-forming
unitsml at 48 h after infection in the mixed transcript trans-
Fig. 2. SARS-CoV full-length transcripts are infectious. Full-length tran-
scripts, in the presence or absence of SARS N transcripts, were electroporated
into BHK cells and overlaid with susceptible VeroE6 cells. A portion of the cells
was examined by fluorescent Ab staining. (A) Cultures transfected with SARS-
CoV full-length transcripts. (B) SARS full-length transcripts plus N transcripts.
(C) Uninfected control. (D) Virus growth was determined for the first 96 h after
transfection by plaque assay; icSARS transcripts alone () and icSARS plus N
transcripts, trials 1 (}) and 2 (‚). (E) icSARS-CoV and WT SARS-CoV plaques in
Vero E6 cells.









fected cultures (Fig. 2D). Recombinant viruses were also de-
tected in cultures transfected with genome-length SARS-CoV
transcripts alone, but titers were reduced. SARS-CoV N tran-
scripts may enhance but are not essential for infectivity of SARS
full-length transcripts. Molecular cloned viruses produced sim-
ilar sized plaques as WT SARS-CoV Urbani (Fig. 2E).
icSARS-CoV Marker Mutations. Rescued icSARS-CoV, but not WT
SARS-CoV, should contain several BglI sites that were engi-
neered as junctions between the SARS BC, DE, and EF
subclones and lack the BglI site at nucleotide position 1577.
Intracellular RNA was isolated from infected cultures, RT-PCR
amplified by using primer pairs f lanking these various sites, and
subjected to restriction-fragment-length polymorphism analysis
with BglI. Clearly, icSARS-CoV contained the marker mutations
inserted within and between the component clones (Fig. 3 A and
B). Selected amplicons were cloned and sequenced, demonstrat-
ing that the icSARS-CoV originated from transcripts derived
from the full-length cDNA construct (Fig. 3C).
Phenotype of Rescued icSARS-CoV. Recombinant icSARS-CoV
replicated as efficiently as WT Urbani, but slightly less efficiently
than the Tor-2 and Tor-7 SARS-CoV isolates (Fig. 4A). All
viruses replicated to titers of 1–5  107 within 24–48 h after
infection. icSARS-CoV subgenomic mRNAs should contain a
common 72-nt leader RNA sequence, which is derived from
the 5 end of the genome. Intracellular RNA was isolated from
Urbani WT and icSARS-CoV-infected cultures. Primer pairs
were derived from the leader RNA sequence and from various
locations at the 3 end of the genome. After RT-PCR amplifi-
cation of leader-containing amplicons, sequence analysis indi-
cated that eight WT and icSARS-CoV subgenomic transcripts
originated at identical CS sites, defined by the core sequence
ACGAAC (Fig. 4B). This sequence represents a truncation of
the AAACGAAC CS site that had been predicted by Rota et al.
(8) and is different from the group I, II, and III CoV CS,
CUAAAC (TGEV), UCTAAAC (MHV), and CUUAACAA
(IBV), respectively. Although some previous studies suggested
that the SARS E protein and ORF X3 might be expressed from
multicistronic mRNA, our findings indicate that independent
transcripts are initiated at the core CS ACGAAC noted at
nucleotide positions 26109 for E transcripts and 26913 for ORF
X3 transcripts, respectively (Fig. 4B). Several may encode two or
more ORFs (Fig. 4B) (11). Using 5 RACE, SARS N transcripts
contained an identical 72-nt 5 leader RNA sequence derived
from the 5 end of the genome (data not shown).
In Vitro Inhibition of SARS-CoV Replication. During MHV and foot
and mouth disease virus infection, the cysteine proteinase
inhibitor E64-d blocks replicase polyprotein processing, thereby
inhibiting viral RNA synthesis and growth (12). E64-d is non-
cytotoxic to cells and does not inhibit cellular RNA synthesis.
Moreover, removal of the E64-d allows recovery of virus repli-
cation (12). To determine whether icSARS-CoV was susceptible
to the inhibitory effects of E64-d, growth comparisons were
performed in the presence and absence of drug. In the absence
of E64-d, WT and icSARS-CoV grew to equivalent titers of
1.0  107 plaque-forming unitsml after 24–48 h after infec-
tion. Untreated, infected VeroE6 cells showed extensive cyto-
pathic effect with cell rounding and loss at 72 h (Fig. 4D).
Treatment of cells with a single dose of E64-d at 1 h after
infection resulted in a significant 3–4 log reduction in virus
yield for both WT and icSARS-CoV at 24 and 48 h after
infection, respectively, with concomitant reductions in viral
cytopathic effect at 72 h and healthy intact monolayers (Fig. 4 C
and D). Under similar conditions, MHV replication was also
reduced by 3.0 logs, from 3.0  107 to 1.5  104 at 10 h, but
rebounded to 1.0  107 plaque-forming unitsml by 24 h after
infection. Thus, the replication of icSARS-CoV appeared to be
inhibited by a single dose of E64-d for a longer duration than
MHV. Details of E64-d effects on SARS polyprotein processing
will be reported in more detail elsewhere.
Discussion
It is hypothesized that the SARS-CoV emerged from exotic
animals in China. Although no one can accurately predict the
future impact of SARS-CoV on the global community, the past
25 years has seen the emergence and global spread of several new
pathogenic CoVs in animals (23–25). Coupled with in vitro
findings, CoVs are serious emerging pathogens capable of rapid
evolution, cross species transmission, and colonization of new
host species (26, 27). Given the exigency of the SARS-CoV
outbreak, the availability of a full-length cDNA will provide a
genetic approach to manipulate the SARS-CoV genome for
vaccine development and to explore the complexity of the
genome. The SARS replicase contains several predicted enzy-
matic activities and undefined domains whose function in rep-
Fig. 3. icSARS-CoV marker mutations. cDNAs spanning the different BglI
junctions were amplified from WT and icSARS-CoV-infected cells. The frag-
ments were purified, and a portion was digested with BglI and separated in
1.2% agarose gels. (A) icSARS-CoV (lanes 2, 3, 6, 7, 10, and 11) and WT
SARS-CoV (lanes 4, 5, 8, 9, 12, and 13). Lanes 2–5, a 1,668-nt amplicon
(nucleotide positions 1007–2675) digested with BglI (lanes 3 and 5); lanes 6–9,
a 799-nt amplicon spanning the SARS-CoV BC junction (positions 8381–9180)
digested with BglI (lanes 7 and 9); lanes 10–13, a 544-nt amplicon (positions
11,721–12,265) spanning the SARS-CoV CD junction digested with BglI (lanes
11 and 13). Lanes 1 and 14, a 1-kb ladder. (B) WT SARS (lanes 4, 5, 8, and 9);
icSARS-CoV (lanes 2, 3, 6, and 7). Lanes 2–5, a 652-nt amplicon spanning the
SARS-CoV DE junction digested with BglI (lanes 3 and 5); lanes 6–9, a 1,594-nt
amplicon (positions 23,665–25,259) spanning the SARS-CoV EF junction di-
gested with BglI (lanes 7 and 9). Lanes 1 and 10, a 1-kb ladder. (C) The 1,594-nt
SARS EF junction-containing amplicon was subcloned and sequenced, dem-
onstrating the mutations introduced within the icSARS-CoV.
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lication remain largely unexplored but may represent targets for
antiviral intervention (11).
Effective biodefense and control of emerging infections re-
quires rapid response methodologies for developing safe and
effective vaccines and therapeutics. For SARS-CoV, the com-
bination of high-throughput screening and class IIS restriction
endonucleases streamlined the isolation and assembly of con-
sensus cDNA fragments and resulted in recovery of recombinant
SARS-CoV within 2 mo of obtaining viral RNA. We have
hypothesized that these approaches could be applied to any
newly emerging RNA or DNA virus pathogen and also allows the
assembly of large genes and genomes by ligation of synthetic
oligonucleotides in vitro (17, 18).
We have constructed full-length cDNAs of representative
group I and group II CoVs. As with MHV and TGEV, N
transcripts enhance recovery of rescued viruses (17,18). Al-
though the exact mechanism is unknown, data from our labo-
ratory indicate that a functional N ORF is critical. N protein may
enhance the translation of viral mRNAs, protect the viral
genome, or enhance subgenomic transcription (K.M.C., B.Y.,
A. C. Sims, and R.S.B., unpublished observation). In agreement
with earlier reports (11), icSARS-CoV-infected cells contain
genome length and at least eight subgenomic mRNAs encoding
a common 72-nt leader RNA sequence fused at a common core
CS ‘‘ACGAAC.’’ The CS core sequence is only encoded at these
critical sites for subgenomic transcription. Several of these
subgenomic mRNAs (mRNA 3, 7, 8, and 9) may be functionally
multicistronic, but the function of these downstream group-
specific ORFs remains unknown. As high homology is necessary
for leaderbody CS fusion and efficient synthesis of subgenomic
mRNAs, we predict that the previously undescribed SARS
transcriptional regulatory sequence may provide a formidable
obstacle against intergroup RNA recombination, especially at
the 3 end of the genome.
The SARS full-length cDNA may allow for the development
of live candidate vaccine strains that contain defined attenuating
mutations. Generating safe and effective CoV vaccines has
proven challenging in both animals and humans because these
viruses often replicate at mucosal surfaces and the most severe
forms of disease oftentimes occur in newborn animals. Vaccines
have not been developed for the human CoVs HCV-229E and
HCV-OC43 because of limited disease severity and short-term
protective immunity. Killed-virus vaccine candidates have not
proven very successful against TGEV, feline infectious perito-
nitis virus, and IBV. Live attenuated and recombinant virus
vaccines have proven effective against TGEV, MHV, and IBV
(32–37). However, feline infectious peritonitis virus vaccination
with killed, recombinant or live-attenuated virus results in the
production of anti-S Abs, leading to disease enhancement and
death after virus challenge (38, 39). Although long-lived mucosal
immunity, immune enhancement, and recombination with ex-
isting strains are potential problems facing the development of
an efficacious SARS vaccine, several animal vaccine approaches
have proven successful and most SARS patients develop immune
responses and recover (2, 4, 40, 41).
Although at an early stage of development, Fouchier et al. (42)
infected four macaques simultaneously through the conjunctiva,
nose, and trachea. The animals became lethargic at 3 d, and virus
was detected in all four infected animals which seroconverted.
The two animals infected at the higher dose were autopsied at
6 d after infection and had lesions in the lung similar to those in
infected humans. The testing of molecularly cloned icSARS-
Fig. 4. Phenotype comparisons between WT and icSARS-CoV. Cultures of cells were infected with an multiplicity of infection of 0.1. At 1 h, cultures were treated
with E64-d at a concentration of 500 gml, and virus titers were determined by plaque assay in VeroE6 cells (C). (A) Growth of Urbani (), icSARS (▫), and the
Tor-2 (Œ) and Tor-7 (‚) CoVs. (B) Leader-containing transcripts encoding various icSARS-CoV subgenomic ORFs. *, predicted ORFs classified by using standard CoV
nomenclature (11). (C) Growth of icSARS and Urbani SARS-CoV in the presence or absence of E64-d. Hatched bars, 24-h titers; black bars, 48-h titers. (D) Urbani
SARS-CoV-infected cells at 72 h after infection.









CoV as an innoculum in primates should provide further evi-
dence for a CoV etiology of SARS. Further refinement of the
nonhuman primate model, coupled with a full-length cDNA
clone for the introduction of precise modifications into rescued
icSARS-CoV, should allow for the development of candidate
vaccines for the clinic. For example, deletion of the noncon-
served, group-specific ORFs encoded within the last one-third of
the genome was not detrimental CoV replication in vitro, but
viruses were attenuated in vivo (22, 28, 29). These ORFs can also
be replaced with foreign genes, providing for heterologous gene
expression from recombinant viruses and from single-hit repli-
con particles (22, 30, 31). Although speculative, some of the
SARS group-specific ORFs may also encode luxury functions
that attenuate pathogenesis in vivo but may have little impact on
in vitro replication.
The availability of a SARS-CoV infectious clone will provide
a tool to study candidate antiviral agents. The current data
indicate that the cysteine proteinase inhibitor E64-d may inhibit
SARS virus replication at any time during infection. The dem-
onstrated ability of E64-d in the MHV model to inhibit multiple
proteinases suggests that it might be less susceptible to virus
escape by mutations in individual proteinases (12). The recent
description of the structure of the CoV 3C-like proteinase (44)
will guide targeted genetic studies of susceptibility to candidate
antivirals and the evolution of drug resistance. In addition, the
replicase gene comprises two-thirds of the SARS-CoV genome
and encodes many proteins of unknown function. The availabil-
ity of a full-length cDNA of the SARS genome should allow for
genetic manipulation of the replicase gene providing new in-
sights into the role of specific proteolytic cleavages and replicase
proteins during viral replication.
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